Sphera Funds Management’s Clearside Biomedical CLSD Stock Holding History

Sphera Funds Management’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-79,008	Closed	-$1.27M	–	111
2018 Q4	$1.27M	Buy	79,008 +2,029	+3%	+$95.2K	0.14%	86
2018 Q3	$7.1M	Buy	76,979 +5,731	+8%	+$681K	0.82%	30
2018 Q2	$11.4M	Buy	71,248 +2,581	+4%	+$435K	1.58%	15
2018 Q1	$11.1M	Buy	68,667 +38,667	+129%	+$4.71M	1.68%	14
2017 Q4	$3.15M	Buy	30,000 +10,000	+50%	+$1.07M	0.37%	67
2017 Q3	$2.62M	Hold	20,000	–	–	0.37%	71
2017 Q2	$2.73M	Hold	20,000	–	–	0.46%	68
2017 Q1	$2.38M	Hold	20,000	–	–	0.47%	63
2016 Q4	$2.68M	Buy	20,000 +4,927	+33%	+$1.24M	0.68%	44
2016 Q3	$3.92M	Sell	15,073 -4,927	-25%	-$603K	0.64%	38
2016 Q2	$2.1M	Buy	+20,000	New	+$2.1M	0.55%	56

Other funds holding CLSD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Sphera Funds Management's CLSD Position: Q1 2019 in Review

Sphera Funds Management sold out of Clearside Biomedical (CLSD) in Q1 2019, closing a stake of 79,008 shares — an estimated $1.27M sold.

Sphera Funds Management first reported a position in CLSD in Q2 2016 and held it in 11 quarters. The position peaked at $11.4M in Q2 2018. 57 funds tracked by Wall St. Rank hold CLSD as of Q1 2019.

Sphera Funds Management reported no remaining Clearside Biomedical position as of Q1 2019 after selling out during the quarter.
Sphera Funds Management sold 79,008 Clearside Biomedical shares in Q1 2019, an estimated $1.27M.
Sphera Funds Management first reported a position in Clearside Biomedical in Q2 2016 and held it in 11 quarters.
Sphera Funds Management's Clearside Biomedical position peaked at $11.4M in Q2 2018.
57 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2019.

Based on Sphera Funds Management's 13F filing for Q1 2019, filed 15 May 2019.